Grace Therapeutics (GRCE) Other Non-Current Liabilities (2019 - 2025)

Grace Therapeutics has disclosed Other Non-Current Liabilities across 7 years of filings, most recently posting $201000.0 for Q3 2025.

• In Q3 2025, Other Non-Current Liabilities fell 92.28% year-over-year to $201000.0; the TTM figure through Sep 2025 stood at $201000.0 (down 92.28% YoY), while the FY2025 annual figure was $1.1 million, down 73.82% from the prior year.
• Other Non-Current Liabilities came in at $201000.0 for Q3 2025 at Grace Therapeutics, down from $1.6 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $5.2 million in Q1 2021 to a low of $10000.0 in Q1 2022.
• Average Other Non-Current Liabilities over 5 years is $2.5 million, with a median of $2.8 million recorded in 2024.
• Year-over-year, Other Non-Current Liabilities surged 118.09% in 2021 and sank 99.81% in 2022.
• Over 5 years, Other Non-Current Liabilities stood at $268000.0 in 2021, then tumbled by 96.27% to $10000.0 in 2022, then jumped by 33220.0% to $3.3 million in 2023, then grew by 13.48% to $3.8 million in 2024, then plunged by 94.68% to $201000.0 in 2025.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $201000.0 in Q3 2025, $1.6 million in Q2 2025, and $1.1 million in Q1 2025.